{"analyses":[{"ciLowerLimit":"-11.205","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"-2.403","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0025","paramType":"Mean Difference (Final Values)","paramValue":"-6.80","statisticalMethod":"Regression, Linear"},{"ciLowerLimit":"-15.246","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.072","groupIds":["OG002","OG003"],"nonInferiorityComment":"The china cohort was not powered for superiority","nonInferiorityType":"OTHER","pValue":"0.1348","paramType":"Mean Difference (Final Values)","paramValue":"-6.59","statisticalMethod":"Regression, Linear"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.065","value":"-52.36"},{"groupId":"OG001","spread":"28.270","value":"-45.66"},{"groupId":"OG002","spread":"24.303","value":"-49.17"},{"groupId":"OG003","spread":"26.814","value":"-42.92"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"279"},{"groupId":"OG001","value":"277"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"65"}],"units":"Participants"}],"description":"The Depth of response was defined as the relative change in the sum of the longest diameters of Response Evaluation Criteria in Solid Tumors (RECIST) Target lesions (TLs) at the nadir, in the absence of new lesions (NLs) or progression of Non-target lesions (NTLs), compared to baseline and was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy","dispersionType":"Standard Deviation","groups":[{"description":"Randomized participants received Osimertinib 80 mg orally once daily (QD)","id":"OG000","title":"Osimertinib 80 mg (Global Cohort)"},{"description":"Randomized participant received Standard of care (SoC) Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Participants received gefitinib 250 mg orally QD or erlotinib 150 mg orally QD.","id":"OG001","title":"SoC EGFR-TKI (Global Cohort)"},{"description":"Randomized participants received Osimertinib 80 mg orally once daily (QD)","id":"OG002","title":"Osimertinib 80 mg (China Cohort)"},{"description":"Randomized participant received Standard of care (SoC) Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFRTKI). Participants received gefitinib 250 mg orally QD or erlotinib 150 mg orally QD.","id":"OG003","title":"SoC EGFR-TKI (China Cohort)"}],"paramType":"MEAN","populationDescription":"The full analysis set (FAS) and China-only FAS. FAS included all randomized participants prior to the end of global recruitment. The China-only FAS included all China participants randomized in mainland-China as part of the global study and all additional China participants recruited in mainland China after global recruitment was completed.","reportingStatus":"POSTED","timeFrame":"At baseline and every 6 weeks for the first 18 months and then every 12 weeks until objective disease progression","title":"Depth of Response","type":"SECONDARY","unitOfMeasure":"percentage of change"}